Lymphoma
|
0.390 |
AlteredExpression
|
group |
BEFREE |
The mRNA and protein expression levels of B cell leukemia/lymphoma (Bcl‑2), Bcl‑2 associated X (Bax), cyclin dependent kinase 4 (CDK4), cyclin D1 and p21 were evaluated using reverse transcription‑polymerase chain reaction and western blot analysis, respectively.
|
29115462 |
2018 |
Lymphoma
|
0.390 |
AlteredExpression
|
group |
BEFREE |
To date, CDK4/6 inhibitors have shown promising clinical activity in breast cancer and lymphomas, but it is not clear which additional Rb-positive cancers might benefit from these agents.
|
29232554 |
2017 |
Lymphoma
|
0.390 |
Biomarker
|
group |
BEFREE |
As drug resistance remains a major challenge and CDK4 and PI3K are dysregulated at a high frequency in human cancers, targeting CDK4 in genome-based combination therapy represents a novel approach to lymphoma and cancer therapy.
|
25082755 |
2014 |
Lymphoma
|
0.390 |
Biomarker
|
group |
BEFREE |
Furthermore, our data suggest that targeting CDK4 may increase the risk for the development and/or progression of lymphoma.
|
24614102 |
2014 |
Lymphoma
|
0.390 |
Biomarker
|
group |
BEFREE |
Statistical analysis of the expression data revealed the combination of CCND1 and CDK4 as the best classifier concerning separation of both lymphoma types.
|
12036888 |
2002 |
Lymphoma
|
0.390 |
Biomarker
|
group |
BEFREE |
To compare the expression status of G1 cyclins, these EBV-associated lymphoma lines (6 EBV[-] human SCID mouse lymphoma lines, 13 human B cell lymphomas and 8 samples of human tonsil tissue) were examined by reverse transcription-polymerase chain reaction-Southern blotting, Western blotting and immunohistochemistry. mRNA expression of cyclin D1 (CCND1), cyclin D2 (CCND2), cyclin E (CCNE), cyclin-dependent kinase 2 (CDK2) and 4 (CDK4) was found in all 3 types of lymphomas.
|
11291051 |
2001 |
Lymphoma
|
0.390 |
Biomarker
|
group |
BEFREE |
In the present study, we analysed 34 de novo diffuse large B cell lymphoma (DLCL) from a population-based lymphoma registry for alterations of the RB1 pathway at the genetic (RB1 and CDK4) and protein (pRb, cyclin D1, cyclin D3, CDK4, and E2F-1) level.
|
10803523 |
2000 |
Lymphoma
|
0.390 |
GeneticVariation
|
group |
BEFREE |
Therefore, considerable efforts have been made to determine the role of CDK4/6-inhibitors in hematologic malignancies: This article will review alterations of components of the cell-cycle machinery in brief and summarize the role of the CDK4/6-inhibitors p16INK4A, p15INK4B, p18INK4C and p19INK4D in leukemias and lymphomas.
|
9031081 |
1996 |
Lymphoma
|
0.390 |
Biomarker
|
group |
BEFREE |
Analysis of the novel cyclin-dependent kinase 4 and 6 inhibitor gene p18 in lymphoma and leukemia cell lines.
|
8628020 |
1996 |
Lymphoma
|
0.390 |
CausalMutation
|
group |
CGI |
|
|
|
Lymphoma
|
0.390 |
GenomicAlterations
|
group |
CGI |
|
|
|